CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
ziv-afliberceptbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00369655
NCT00369655Phase 2Completed
CompareCT.gov

Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline and/or Taxane

National Cancer Institute (NCI)·interventional·Posted Aug 29, 2006·Updated May 5, 2014

In Brief

A Phase 2 clinical trial evaluating ziv-aflibercept for Metastatic Breast Cancer and 2 related conditions. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This phase II trial is studying how well VEGF Trap works in treating patients with metastatic breast cancer. VEGF Trap may stop the growth of tumor cells by blocking blood flow to the tumor

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 29, 2006
Enrollment StartJan 1, 2007
Primary CompletionMar 1, 2008
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.8 years ago

Interventions

ziv-afliberceptbiological